Opendata, web and dolomites

BILITOLERANCE SIGNED

Control of disease tolerance to infection by Biliverdin Reductase A

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BILITOLERANCE project word cloud

Explore the words cloud of the BILITOLERANCE project. It provides you a very rough idea of what is the project "BILITOLERANCE" about.

multiple    immunopathology    infection    tissue    imposed    confer    conserved    carry    possibly    heme    tissues    parenchyma    potent    functional    mechanism    activation    host    disease    macrophages    catabolizing    pro    anti    genes    hypothesis    tolerance    selective    protein    iron    resistance    pathogen    emergence    sequestering    provides    of    reductase    unexplored    receptor    peroxidation    aryl    said    modulate    central    offs    deleterious    function    ferritin    signals    expression    preserve    conversion    oxidant    containment    negative    hydrocarbon    strategy    lipophilic    limits    fitness    defense    tested    evolution    chain    coupled    relies    led    limit    mechanisms    cells    health    shaped    bvra    illustrated    trade    oxidative    survival    lipid    infections    presumably    ahr    pressure    direct    countervailing    bilirubin    immune    effector    biliverdin    bilitolerance    damage    catabolism    compromising    clearance    oxygenase    primarily    stress    expulsion    enzyme    output    exerting    resident    pathogens    characterizing    evolutionary   

Project "BILITOLERANCE" data sheet

The following table provides information about the project.

Coordinator
FUNDACAO CALOUSTE GULBENKIAN 

Organization address
address: AVENIDA BERNA 45
city: LISBOA
postcode: 1000
website: www.igc.gulbenkian.pt

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Total cost 160˙635 €
 EC max contribution 160˙635 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2021-02-04

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACAO CALOUSTE GULBENKIAN PT (LISBOA) coordinator 160˙635.00

Map

 Project objective

The immune system was shaped through evolution, primarily through the selective pressure imposed by pathogens. This led to the emergence of multiple mechanisms that limit the negative impact of pathogens on host health and fitness. The best recognized defense strategy against infections relies on resistance mechanisms that aim at pathogen containment, expulsion or clearance. While crucial for host survival to infection, resistance mechanisms can carry significant trade-offs, often driven by oxidative stress and damage imposed to host parenchyma cells, and in some cases compromising the functional output of host tissues, i.e. immunopathology. Presumably for this reason, resistance mechanisms are coupled to countervailing oxidative stress responses that preserve parenchyma tissue function. These provide tissue damage control without exerting a direct negative impact on pathogens and as such are said to confer disease tolerance to infection. This defense strategy relies on the expression of a number of evolutionary conserved effector genes controlling the pro-oxidant effects of iron and heme, as illustrated for the heme catabolizing enzyme heme oxygenase 1 or the iron sequestering protein ferritin H chain. BILITOLERANCE aims at identifying and characterizing an unexplored and possibly central component of this tissue damage control mechanism that relies on the conversion of the end-product of heme catabolism biliverdin into bilirubin, by biliverdin reductase A (BVRA). The central hypothesis to be tested by BILITOLERANCE is that bilirubin generated by BVRA provides a potent lipophilic anti-oxidant defense mechanism that limits the deleterious effects of lipid peroxidation. Moreover BILITOLERANCE will test the hypothesis that bilirubin also signals via the aryl hydrocarbon receptor (AhR) to modulate the activation of tissue-resident macrophages and promote tissue damage control and disease tolerance to infection.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BILITOLERANCE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BILITOLERANCE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

pyrroQuin (2020)

Synthesis and Biological Evaluation of Pyrroquinoline Pseudo-Natural Products

Read More  

EngPTC2 (2019)

Exploring new technologies for the next generation pulse tube cryocooler below 2K

Read More  

NSTree (2020)

Understanding substrate delivery for cell wall biosynthesis in plants

Read More